Business Wire

Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros

Share

Regulatory News:

Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, today announces the large successful capital increase through a private placement open to certain categories of beneficiaries launched the previous day and achieved using an accelerated bookbuilding process. Given the very high demand from French and international investors, Valbiotis decided to set the amount of the capital increase at 15 million euros, compared to approximately 12 million euros initially forecast.

Sébastien PELTIER, CEO of Valbiotis stated: "I am extremely grateful to all the new investors who participated in this capital increase, as well as all our historic shareholders who continue to support our company in its mission and its development. This capital increase is key, as it will enable us to accelerate our development program for the prevention of high blood pressure with the aim of marketing by 2023, up to three years ahead of our initial schedule. It will also contribute to the achievement of our preclinical programs across our entire portfolio and to the strengthening of our supply chain in view of, among other things, the future commercialization of TOTUM•63 in prediabetes by Nestlé Health Science. Thanks to these new resources, that secure the execution of our roadmap in the long term, we have everything we need to succeed!”

Allocation of funds to the development strategy of Valbiotis

The net proceeds of the capital increase of approximately 14.2 M€ are primarily intended to finance the acceleration of the development of TOTUM•854 (prevention of arterial hypertension) with the launch of three clinical trials at the end of this year including a Phase II/III clinical trial prior to a health claim application. In partnership with a major healthcare player, TOTUM•854 could then be marketed at the end of this study, up to 3 years ahead of the initial schedule.

This acceleration comes in the wake of the positive preclinical results obtained with this active substance, presented at the annual ESH – ISH congress (press release of April 12, 2021) and available on the Company website (www.valbiotis.com/en). These results obtained in vivo on predictive models of human hypertension have shown that TOTUM•854 effectively prevents arterial hypertension, considered as the number one chronic disease worldwide with over 124 million people with moderately high blood pressure in the United States and the 5 main European countries (Germany, Spain, France, Italy, and the United Kingdom) alone. This represents an addressable market for Valbiotis worth an estimated 1.15 billion euros (source: AEC Partners, 2020).

The capital increase will also help to extend Valbiotis' funding horizon and enable the Company to reach the next steps in value creation of its various products:

  • funding of preclinical research on the other products in the portfolio;
  • reinforcement of staff, mainly clinical and supply chain teams, to prepare the upcoming marketing of TOTUM•63 in prediabetes by Nestlé Health Science;
  • financing the Company’s overall costs until first semester 2024.

Main characteristics of the capital increase

Valbiotis has issued 1,930,000 new shares at a unit price of 7.80 euros, share premium included, which corresponds to a nominal value of 0.10 euros and a share premium of 7.70 euros, for a gross amount of 15,054,000 euros. This represents 25% of the share capital of Valbiotis before the capital increase and an overall dilution of 20%.

The capital increase was executed with the removal of shareholders’ preferential subscription rights through a private placement using an accelerated bookbuilding process with both French and international qualified investors belonging to the category of persons referred to in the 13th resolution of the Shareholders’ Annual General Meeting held on May 28, 2020.

The Board set the subscription price at 7.80 euros per new share. This price, fixed under the conditions provided for in the above-mentioned 13th resolution, represents a 5.1% discount compared to the closing price of the Company shares on April 14, 2021.

Incidence of the capital increase on the capital distribution

This transaction will result in an increase of the share capital of Valbiotis from 777,626.20 euros to 970,626.20 euros divided by 9,706,262 shares with a nominal value of 0.10 euros each, and is broken down as follows:

Before offering

After offering

Shareholders

Number of

shares

% of

capital

Number of

shares

% of

capital

Stake of Board members (1)

1,006,051

12.9%

1,006,051

10.4%

Sébastien PELTIER

(via Djanka Investissement and as an individual)

647,100

8.3%

647,100

6.7%

Jocelyn PINEAU

(via Financière ELOUJON and as an individual)

349,751

4.5%

349,751

3.6%

Pascal SIRVENT

9,200

0.1%

9,200

0.1%

Stake of Supervisory Board members (1)

13,400

0.2%

13,400

0.1%

Laurent LEVY

10,400

0.1%

10,400

0.1%

Sébastien BESSY

3,000

0.0%

3,000

0.0%

Liquidity contract (2)

10,679

0.1%

10,679

0.1%

Public

6,746,132

86.8%

8,676,132

89.4%

TOTAL

7,776,262

100%

9,706,262

100%

(1)

The other members of the Board and Supervisory Board do not hold any shares. It is recalled that all the members of the Board and the Supervisory Board together hold 867,124 share warrants and share warrants for entrepreneurs out of a total of 1,140,046 share warrants and share warrants for entrepreneurs issued.

(2)

Data from the session on March 31, 2020.

The allocation of voting rights is as follows:

Before offering

After offering

Shareholders

Number of

shares

% of

capital

Number of

shares

% of

capital

Stake of Board members (1)

1,863,551

21.5%

1,863,551

17.6%

Sébastien PELTIER

(via Djanka Investissement and as an individual)

1,252,100

14.4%

1,252,100

11.8%

Jocelyn PINEAU

(via Financière ELOUJON and as an individual)

602,251

6.9%

602,251

5.7%

Pascal SIRVENT

9,200

0.1%

9,200

0.1%

Stake of Supervisory Board members (1)

13,400

0.2%

13,400

0.1%

Laurent LEVY

10,400

0.1%

10,400

0.1%

Sébastien BESSY

3,000

0.03%

3,000

0.03%

Liquidity contract (2)

-

0.0%

-

0.0%

Public

6,808,460

78.4%

8,738,460

82.3%

TOTAL

8,685,411

100%

10,615,411

100%

(1)

The other members of the Board and Supervisory Board do not hold any shares. It is recalled that all the members of the Board and the Supervisory Board together hold 867,124 share warrants and share warrants for entrepreneurs out of a total of 1,140,046 share warrants and share warrants for entrepreneurs issued.

(2)

Data from the session on March 31, 2020.

Impact on the situation of the shareholder

Based on the post-transaction share capital, the stake of a shareholder holding 1% of the capital of the Company before the capital increase and not having subscribed to the latter now holds 0.80%.

Shareholder stake

Non-diluted

basis

Diluted basis (1)

1%

0.88%

0.80%

0.72%

(1) Taking into account the subscription of 1,930,000 new shares likely to be created to date.

The impact on the equity per share is as follows:

Equity (1) per share

on December 31, 2020

Non-diluted

basis

Diluted basis (1)

0.92 €

0,81 €

0.74 €

0.66 €

(1) Established according to the IFRS and before charging expenses against the issue premium, based on audited accounts, closed and not approved at December 31, 2020.
(2) Taking into account the subscription of 1,930,000 new shares likely to be created to date

Admission to trading of new shares

The new shares will bear dividend rights and will be admitted to trading on the Euronext Growth Paris market under the same ISIN code: FR0013254851 – ALVAL. They will be subject to all statutory provisions and will be ranked with the existing shares upon completion of the capital increase. The settlement of the new shares and their admission to trading on the Euronext Growth Paris market is scheduled within 3 working days.

The information presented in this press release is so following the placement of shares through an accelerated bookbuilding process, now closed, but remains subject to the correct execution of the settlement transactions.

Pursuant to the provisions of Article 211-3 of the General Regulation of the Autorité des marchés financiers and Article 1(4) of Regulation (EU) 2017/1129, the Offer has not resulted in or will not result in the preparation of a prospectus submitted to the AMF for approval.

About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150

Warning

This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties mentioned in this press release. This document is available on the Company's website (www.valbiotis.com).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

As a reminder, pursuant to the provisions of Article 211-3 of the General Regulations of the Autorité des marchés financiers and Article 1, 4 of Regulation (EU) 2017/1129, the offer of the Company's shares in the context of the capital increase carried out for the benefit of a category of persons meeting specific characteristics, in particular qualified French and international investors, will not give rise to a prospectus subject to the visa of the Autorité des marchés financiers.

Detailed information about Valbiotis, including its business, results and risk factors, has been presented in the annual financial report for the financial year ending December 31, 2020, in the half-year financial report for the period ending June 30, 2020 and in the registration agreement approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). These documents, as well as other regulated information and press releases, can be consulted on the Company's website (www.valbiotis.com).

This press release is for information purposes only. This press release does not constitute and shall not be deemed to constitute an offer to the public, an offer to subscribe, an offer to sell or a solicitation of interest to the public in connection with any transaction by way of public offering of securities in any jurisdiction.

Securities may be offered or sold in the United States only pursuant to registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from such registration requirement. The securities of the Company that are the subject of this press release have not been and will not be registered under the Securities Act, and the Company does not intend to conduct a public offering of the securities that are the subject of this press release in the United States.

The release, publication or distribution of this press release in certain countries may violate applicable laws. The information contained in this press release does not constitute an offer of securities in France, the United States, Canada, Australia, Japan or any other country. This press release may not be published, transmitted or distributed, directly or indirectly, in the United States, Canada, Australia or Japan. This document does not constitute an offer to sell or a public offering of Valbiotis shares in the United States or in any other country.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate communication / Valbiotis
Carole ROCHER / Marc DELAUNAY
+33 5 46 28 62 58
media@valbiotis.com

Financial communication / Actifin
Stéphane RUIZ
+33 1 56 88 11 14
sruiz@actifin.fr

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Raven Industries Launches the OMNi Brand12.5.2021 15:15:00 CEST | Press release

Raven Industries, Inc.(the Company; NASDAQ:RAVN) a leader in agriculture technology, announced today the launch of its new product brand and autonomous growth platform, OMNi. This new product brand highlights Raven’s advancements in autonomous solutions for agriculture with a strategic offering of two integrated products: OMNiDRIVE™ and OMNiPOWER™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005126/en/ The OMNi name (meaning "all") will take center stage within Raven. “Empowering ‘all’ is exactly what OMNiPOWER™ and OMNiDRIVE™ bring to the agriculture industry. OMNi enables holistic, hands-free precision; it gives the farmer total control of their time and maximizes operational productivity and efficiency,” said Nick Langerock, Director of Strategic Marketing for Raven. “As we bring OMNi to market, we want farmers to understand that some of their pain points are now more manageable through autonomous solutions. OMNi

SentinelOne Receives Highest Score for the Type A Use Case (“Lean Forward” Organizations) in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms12.5.2021 15:00:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest score in use case Type A in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. SentinelOne received the highest score for all three customer types out of 19 vendors. Gartner says, “Type A organizations, also referred to as 'lean forward' organizations, adopt new technologies very early in the adoption cycle.” “We believe receiving the highest product score among early technology adopters in the 2021 Critical Capabilities for Endpoint Protection Platforms validates our commitment to disrupt and broaden the endpoint space,” said Raj Rajamani, Chief Product Officer, SentinelOne. “These organizations tend to focus on innovative solutions that address their business, technology and security needs. Receiving the highest score for 'lean forward' companies highlights our ability to take cybersecurity defenses to new levels of speed, e

New CloudBlue Revenue Management Solution Solves for Recurring Billing Reconciliation12.5.2021 15:00:00 CEST | Press release

CloudBlue, a leading cloud ecosystem technology company, announced today the launch of CloudBlue Rev, a solution that enables partners to ‘rev’ up their channel revenue management. CloudBlue Rev simplifies and streamlines channel revenue management to enhance efficiency, save time and increase profitability. Available now in the United Kingdom with planned rollouts across the world, learn more here. The new solution is based on the recently acquired HarmonyPSA architecture and is the latest addition to CloudBlue’s rapidly expanding portfolio of technologies and services for the channel. CloudBlue Rev helps channel reseller partners regain valuable time as they transition to an everything-as-a-service business by automating quoting, billing and reconciliation. By streamlining these processes into a single platform, resellers will now be able to automate profit tracking across sales motions with integrated discounting and markup, as well as quickly set margins and gain insight into contr

Hiro Capital Leads $6.4m Investment in Game Innovators Twin Suns Corp and FRVR12.5.2021 15:00:00 CEST | Press release

Twin Suns Corp and FRVR will use Hiro’s $6.4m of investment to expand development and to accelerate growth. Twin Suns Corp is a new AAA-game studio, founded by >20-year industry veterans - Tim Longo Jr. (Star Wars: Republic Commando, Halo, Tomb Raider), Forest Swartout Large (Hitman and Tomb Raider), and Jeff Morris (Gears of War and Unreal Tournament). Twin Suns Corp is building a next-gen AAA cross-platform title that will launch an exciting new IP franchise; with additional team members that have worked on Star Wars, Tomb Raider, Hitman, Halo, Elder Scrolls, Fallout, Gears of War, Unreal Tournament and Avengers. FRVR is an instant games ecosystem platform powering frictionless game play on any device, founded by Chris Benjaminsen (Yahoo, PlayerScale) and Brian Meidell (Cape, GameAnalytics) With more than 1bn players, FRVR has partnerships that puts their tech and games onto billions of devices. Twin Suns Corp and FRVR join other creator-founded Games teams Polyarc, Snowprint, Lightf

Nuclera Acquires E Ink Digital Microfluidics Unit12.5.2021 14:53:00 CEST | Press release

Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005575/en/ Nuclera desktop bioprinter powered by digital microfluidic technology. (Photo: Business Wire) Nuclera has been working in a strategic partnership with E Ink since 2018 to deploy Nuclera’s proprietary biopolymer synthesis technologies on E Ink’s digital microfluidic devices. Instead of the physical channels found in convention

Esri Partners with International Community to Scale GIS Technology for Sustainable Development12.5.2021 14:00:00 CEST | Press release

Esri, the global leader in location intelligence, today announced its contribution to an open, community-driven partnership working to accelerate the achievement of the United Nations Sustainable Development Goals (SDGs). Governments, international organizations, foundations, universities, and civil society groups are joining the initiative to offer resources and expertise, including capacity-building efforts, that will enable virtual Centers of Excellence for Geospatial Information to provide greater access to SDG data for nations in need. “This collaboration will bring the innovations of geospatial information science to a wider public,” said Jeffrey Sachs, University Professor and Director of the Center for Sustainable Development, Columbia University, President of the UN Sustainable Development Solutions Network, SDG Advocate under UN Secretary-General António Guterres, and Chair of the Lancet COVID-19 Commission. “The virtual centers will empower communities around the world with

Thales Expands Its Access Management Capabilities to Offer a Unified Authentication Platform12.5.2021 14:00:00 CEST | Press release

Thales has announced an expansion of its SafeNet Trusted Access solution, offering customers full access management protection across all applications or services in any IT environment. Whether it’s in the cloud, on-premise or through an API, Thales’ customers will now be able to benefit from modern authentication capabilities to ensure applications can only be accessed by those authorised to do so. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210512005414/en/ ©Thales On-Premises lingers as API and Cloud adoption rises With the growing use of cloud computing, access management has broadened its scope to address authorisation and authentication beyond human identities. Businesses are increasingly relying on APIs to integrate services and utilise the exchange of data. However, increased reliance on unvalidated APIs can leave businesses vulnerable to an unauthorised or compromised API accessing their applications and services